EFTR News and Press, eFFECTOR Therapeutics Inc. From 05/26/23

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that it has entered into a definitive agreemen...

Partial responses observed in 5 of 19 (26%) evaluable patients treated with zotatifin 0.07 mg/kg combined with fulvestrant and abemaciclib (ZFA triplet) in heavily pretreated population Partial response observed in 1 of 3 (33%) patients treated with zotatifin 0.1 mg/kg combined with fulvest...

2023-05-11 12:38:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Turning $1,000 into $10,000 in a year in the stock market is undoubtedly a lofty goal. Make no bones about it, it’s not particularly likely to happen. Indeed, such an endeavor requires a...

2023-05-10 09:59:08 ET eFFECTOR Therapeutics press release ( NASDAQ: EFTR ): Q1 GAAP EPS of -$0.24. The company had cash, cash equivalents, and short-term investments totaling $19.0 million as of March 31, 2023, compared to $26.3 million as of December 31, 2022. The compan...

Updated data from two fully enrolled Phase 2 expansion cohorts testing zotatifin-based combinations in estrogen receptor-positive (ER+) Metastatic Breast Cancer to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 on June 4, 2023 Company will host conf...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced a poster highlighting result...

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a clinical collaboration with Jennifer Caswe...

2023-03-08 18:07:01 ET eFFECTOR Therapeutics press release ( NASDAQ: EFTR ): Q4 GAAP EPS of -$0.22 beats by $0.02 . Revenue of $0.67M (+116.1% Y/Y) beats by $0.01M . For further details see: eFFECTOR Therapeutics GAAP EPS of -$0.22 beats by $0.02, revenue...

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to start the day with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are earnings reports, clinical tria...